Business
Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) today announced that seven posters will be presented at the 24th Annual Meeting
About this update from Veracyte, Inc.
[{"type":"text","content":" SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT) today announced that seven posters will be presented at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023), where they will demonstrate the clinical performance of Veracyte’s Decipher Prostate Genomic Classifier in identifying patients whose prostate cancer is likely to progress and require treatment. Collectively, the posters will report data from more than 60,000 patients. The meeting will take place in Washington, DC, from November 28 to December 1.\n\n\nThe American Cancer Society estimates that there will be nearly 290,000 new cases of prostate cancer in the U.S. this year. An ongoing challenge in the management of prostate cancer is distinguishing between patients whose tumors require careful monitoring, known as active surveillance, and those who require intervention. Routinely used clinical factors, such as Gleason score and prostate-specific antigen (PSA) level, are not sufficient to determine which prostate cancers are likely to progress and which are not.\n\n\n“These presentations by users of the Decipher Prostate Genomic Classifier will add to the growing body of clinical evidence supporting the use of the test to help physicians guide care for their patients with prostate cancer,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. “This breadth of real-world data truly distinguishes our genomic classifier from other molecular tests available today and serves as a strong foundation for using Decipher results to provide a more complete understanding of each patient’s cancer for more personalized care.”\n\n\nThe following posters will be presented at the SUO 2023 meeting on Friday, December 1:\n\n\nTitle: Assessing molecular heterogeneity of prostate cancer biopsy sampling: Insights from the MAST trial\nPresenter: Tarek Ajami, M.D., University of Miami\nPoster: #214\nTime: 10 a.m. to 11 a.m. ET\n\n\nTitle: Decipher® Genomic Classifier on initial prostate biopsy is associated with Gleason score upgrading on final radical prostatectomy pathology\nPresenter: John Sheng, M.D., Washington University School of Medicine in St. Louis\nPoster: #226\nTime: 12:45 p.m. to 1:45 p.m. ET\n\n\nTitle: Decipher® Genomic Classifier score on initial biopsy is associated with progression from active surveillance to treatment...